GLP-1 agonists have been reported to reduce the risk of cardiovascular disease; however, SGLT2 inhibitors cause a relatively significant reduction in systolic blood pressure and play a unique role in the prevention of heart failure relative to GLP-1 agonists (37). Here, SLC5A2 is linked to heart failure.